Spots Global Cancer Trial Database for refractory central nervous system lymphoma

Every month we try and update this database with for refractory central nervous system lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma	NCT04845139	Refractory Cent... Relapsed Primar... Primary Central...	Nivolumab	18 Years - 80 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Acalabrutinib in CNSL	NCT04906902	Central Nervous... Refractory Cent... Recurrent Centr...	Acalabrutinib	18 Years -	Dana-Farber Cancer Institute
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma	NCT04845139	Refractory Cent... Relapsed Primar... Primary Central...	Nivolumab	18 Years - 80 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma	NCT04845139	Refractory Cent... Relapsed Primar... Primary Central...	Nivolumab	18 Years - 80 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: